Ocuphire Pharma Investor Day Presentation Deck
DR
DME
What's Important?
APX3330 has the Potential to be 1st Line of Therapy for DR Patients
Efficacy Signal
Percent of patients on APX3330 with a ≥ 2 step
improvement on the DRSS score at week 24
compared to placebo in 2 well-controlled, multi-
center clinical trials
Safety
Approval depends on a product's benefit outweighing
its risks in the intended population as demonstrated in,
multi-center, 2 years clinical trial
Non-Invasive Treatment Option
FDA does not require comparative arm of approved
anti-VEGF injections such as Eylea for DR
38
Eylea® label; APX3330 Investigator Brochure, ZETA-1 clinical trial
FDA
Guidance
Physician/
Patients
Efficacy Signal
Clinically meaningful decrease in diabetic
retinopathy severity with APX3330
Early intervention with oral may reduce
progression to vision threatening DR into DME
●
●
Safety
Non-Invasive Treatment Option
Eylea, although approved, is currently not used as
standard of care because of the treatment burden
for asymptomatic DR patients
Ability to be prescribed by all eye care doctors
Oral option increases global access, especially in
underserved regions
●
No major organ toxicities
Well-tolerated (e.g., AEs acceptable if mild and
infrequent for oral)
●
Ocuphire
PHARMAView entire presentation